Taysha Gene Therapies to Participate in Upcoming April Investor Healthcare Conferences

Rhea-AI Summary

Taysha Gene Therapies (Nasdaq: TSHA) will participate in the Guggenheim Genomic Medicines and Rare Disease Day Conference on April 1, 2022, at 4:00 PM ET, and the 21st Annual Needham Virtual Healthcare Conference on April 11, 2022, at 11:45 AM ET. The events will feature discussions led by key executives including RA Session II, Suyash Prasad, and Kamran Alam. Taysha focuses on developing AAV-based gene therapies aimed at curing monogenic diseases of the CNS.

Guggenheim Genomic Medicines and Rare Disease Conference on April 1, 2022 at 4:00 pm ET

21^st Annual Needham Virtual Healthcare Conference April 11, 2022 at 11:45 am ET

DALLAS--(BUSINESS WIRE)-- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced its participation in upcoming fireside chats at the Guggenheim Genomic Medicines and Rare Disease Day Conference and the 21^st Annual Needham Virtual Healthcare Conference.

Conference Details:
Event:		Guggenheim Genomic Medicines and Rare Disease Day Conference
Date:		April 1, 2022
Time:		4:00 pm ET
Format:		Fireside Chat
Participants:		RA Session II, President, Founder and CEO
		Dr. Suyash Prasad, Chief Medical Officer and Head of R&D
		Kamran Alam, Chief Financial Officer
Conference Details:
Event:		21st Annual Needham Virtual Healthcare Conference
Date:		April 11, 2022
Time:		11:45 am ET
Format:		Fireside Chat
Participants:		RA Session II, President, Founder and CEO
		Dr. Suyash Prasad, Chief Medical Officer and Head of R&D
		Kamran Alam, Chief Financial Officer

About Taysha Gene Therapies

Taysha Gene Therapies (Nasdaq: TSHA) is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, we aim to rapidly translate our treatments from bench to bedside. We have combined our team’s proven experience in gene therapy drug development and commercialization with the world-class UT Southwestern Gene Therapy Program to build an extensive, AAV gene therapy pipeline focused on both rare and large-market indications. Together, we leverage our fully integrated platform—an engine for potential new cures—with a goal of dramatically improving patients’ lives. More information is available at www.tayshagtx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220323005345/en/

Company Contact:

Kimberly Lee, D.O.

Chief Corporate Affairs Officer

Taysha Gene Therapies

klee@tayshagtx.com

Media Contact:

Carolyn Hawley

Canale Communications

carolyn.hawley@canalecomm.com

Source: Taysha Gene Therapies, Inc.

FAQ

What conferences is Taysha Gene Therapies participating in April 2022?

Taysha Gene Therapies will participate in the Guggenheim Genomic Medicines and Rare Disease Day Conference on April 1, 2022, and the 21st Annual Needham Virtual Healthcare Conference on April 11, 2022.

What is the date and time for Taysha's participation in the Guggenheim Conference?

Taysha's participation in the Guggenheim Genomic Medicines and Rare Disease Day Conference is scheduled for April 1, 2022, at 4:00 PM ET.

Who will represent Taysha Gene Therapies at the Needham Virtual Healthcare Conference?

Key representatives from Taysha Gene Therapies at the Needham Virtual Healthcare Conference include RA Session II, Suyash Prasad, and Kamran Alam.

What is the focus of Taysha Gene Therapies?

Taysha Gene Therapies focuses on developing and commercializing AAV-based gene therapies for monogenic diseases of the central nervous system.

What is the stock symbol for Taysha Gene Therapies?

The stock symbol for Taysha Gene Therapies is TSHA.